GLOW Blend

Areas of active research — not promised effects

Each tag links to other compounds with research into that goal. Research use only: these are areas of study, not human-use claims.

Related by research scope · open each to compare

The GLOW Blend has no FDA regulatory designation as a combination product. BPC-157 and TB-500 were removed from the FDA Category 2 bulk drug substances list effective approximately April 22–23, 2026, and are scheduled for Pharmacy Compounding Advisory Committee (PCAC) review on July 23–24, 2026 (docket FDA-2025-N-6895). Injectable GHK-Cu was similarly removed from Category 2 in April 2026; non-injectable GHK-Cu remains under separate review with a PCAC consultation expected by February 2027. Removal from Category 2 does not confer Category 1 status or compounding authorization; formal rulemaking is still required. None of the three components is FDA-approved as a drug. The blend as sold is a research-use-only chemical.

Transparent blend · bci-1.0 · never paid-placement

Primary name

GLOW Blend

Origin

GLOW Blend is a vendor-formulated co-lyophilized combination of three individually characterized research peptides: BPC-157 (a synthetic 15-aa gastric mucosal-derived sequence), TB-500 (a synthetic analog of the actin-sequestering protein Thymosin Beta-4), and GHK-Cu (the endogenous tripeptide glycyl-L-histidyl-L-lysine complexed with copper(II) ions). The blend has no independent regulatory designation, no CAS number, and no PubChem entry; its identity is fully defined by its component peptides.

Appearance

White to off-white lyophilized powder (co-lyophilized blend)

Solubility

Reconstitutes in sterile water or bacteriostatic water; GHK-Cu component imparts…

Sequence not available in current seed.

Stability: Each component has distinct stability profiles; GHK-Cu is susceptible to copper oxidation and may degrade at elevated temperatures or in the presence of oxidizi

Vial sizes

70 mg

Purity grades

research grade / ≥98% HPLC (vendor-stated)

Salt forms

Free base (primary)

• GHS hazard class on file
• PPE & spill response
• Disposal guidance
• Not-for-human-consumption posture

Synthetic 15-amino-acid gastric pentadecapeptide studied in animal models for tissue repair, angiogenesis, and GI protection.

BPC-157 has been shown in rodent and cell-culture studies to upregulate vascular endothelial growth factor receptor 2 (VEGFR2) and activate downstream Akt–eNOS signaling, promoting endothelial nitric oxide production and new vessel formation. The peptide also engages the focal adhesion kinase (FAK)–paxillin pathway, facilitating endothelial cell migration during angiogenesis. Additional preclinical data indicate modulation of nitric oxide synthesis more broadly, with context-dependent protective effects against cytotoxic NO excess while preserving physiological NO-mediated functions. These converging angiogenic and cytoprotective pathways are proposed to underlie observations of accelerated wound closure, tendon reattachment, and gastrointestinal mucosal recovery in animal injury models.

Molar mass

1419.5 g/mol

Synthetic 9-amino-acid fragment (Ac-LKKTETQ) of thymosin beta-4 studied in animal models for tissue repair, cell migration, and angiogenesis.

TB-500 binds monomeric G-actin through the same LKKT(X)E motif present in the full thymosin beta-4 protein, sequestering free actin monomers and preventing their incorporation into filamentous F-actin networks; this shifts the intracellular actin equilibrium in a manner that facilitates lamellipodia formation and directed cell migration. Concurrently, the peptide activates integrin-linked kinase (ILK) signaling, promoting downstream phosphorylation events that stimulate keratinocyte and endothelial cell motility. In rodent wound and ischemia models, these effects are accompanied by upregulation of vascular endothelial growth factor (VEGF) and accelerated capillary sprouting, suggesting a secondary pro-angiogenic axis. NF-kB pathway modulation has also been reported in preclinical inflammation models, though the mechanistic hierarchy relative to actin sequestration remains unresolved.

Molar mass

889.0 g/mol

Endogenous copper-chelating tripeptide that modulates collagen remodeling, fibroblast activity, and wound healing; researched topically and in injectable form.

GHK-Cu binds copper(II) with high affinity and delivers it to cells involved in tissue repair. In fibroblast and keratinocyte models, the complex upregulates genes encoding collagen I and III, elastin, decorin, and glycosaminoglycans while simultaneously modulating matrix metalloproteinase activity to favor balanced matrix remodeling over excessive degradation or fibrosis. GHK-Cu also stimulates angiogenesis and exhibits antioxidant activity partly through superoxide dismutase (SOD)-like copper chemistry, and has been reported in preclinical studies to suppress pro-inflammatory NF-κB signaling pathways.

Molar mass

400.90 g/mol

How much research exists, and of what maturity — never a verdict on whether it works.

Mechanism of action

• Each component contributes a mechanistically distinct but convergent pathway to tissue repair
• BPC-157 activates the VEGFR2–Akt–eNOS axis and the FAK–paxillin pathway, promoting angiogenesis and fibroblast migration in preclinical injury models
• TB-500 sequesters G-actin monomers via its LKKTETQ motif, maintaining a mobilizable cytoskeletal reserve that facilitates keratinocyte, fibroblast, and endothelial cell migration in response to injury signals
• GHK-Cu upregulates collagen and glycosaminoglycan biosynthesis through COL1A1/COL3A1 gene expression and TGF-β1 signaling, while also modulating matrix metalloproteinase activity to support extracellular matrix remodeling

Pharmacokinetics (ADME)

Half-life

BPC-157: ~5–15 min IV (rodent); TB-500: hours (subcutaneous, rodent; serial C-terminal cleavage to active metabolites reported); GHK-Cu: minutes (systemic, animal models). Blend-specific PK data absent.

Clearance

Each component is subject to proteolytic degradation; GHK-Cu also undergoes copper dissociation under physiological pH. No blend-level clearance data available.

PK–PD note: A PK–PD disconnect has been described for BPC-157 individually (rapid plasma clearance with prolonged downstream signaling), and active TB-500 metabolites (e.g., Ac-LKKTE) appear to retain wound-heali…

Reading the evidence

• Evidence quality and gaps vary by application — see the cited grades above.
• Indexed-article counts span all evidence tiers, not only completed human trials.
• No first-party human-dosing, efficacy, or benefit claims are made here.

Key reviews & evidence-gap sources

• Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025 Jul 31. PMID 40756949. — Systematic review of 36 studies (1993-2024) from PubMed/Cochrane/Embase; all included studies were preclinical (animal/in-vitro); no human RCTs of BPC-157 identified.
• Dou Y, et al. The potential of GHK as an anti-aging peptide. Aging Pathobiol Ther. 2020;2(1):58-61. PMC8789089. — Narrative review of GHK/GHK-Cu mechanisms (tissue remodeling, angiogenesis, anti-inflammatory); cites topical clinical skin studies but no injectable human RCTs.
• Peptide Protocol Wiki — The Glow Blend: GHK-Cu, BPC-157, and TB-500 Evidence-Based Guide — Aggregator evidence guide; states no published human trial has evaluated the combined blend; component-level evidence summary.

1 registered trial — 0 currently recruiting.

NA
NCT05646953
Safety and Efficacy Study of Vasu Facial Beauty Oil

COMPLETED

Summary (literature)

No safety data exist for the GLOW Blend as a combined formulation. Safety profiles must be inferred from each component individually, all studied exclusively in preclinical settings. BPC-157 has shown a generally favorable tolerability profile in rodent and canine studies with no…

WADA status

Two of three components are prohibited by WADA: BPC-157 is listed under S0 (Non-Approved Substances), prohibited at all times since January 2022; TB-500 (Thymos…

Dominant research route: SC

Most common route for the GLOW blend in community-documented protocols; BPC-157, TB-500, and GHK-Cu each have SC injection data in preclinical/research literature (rodent and cell models)

Bioavailability: No published pharmacokinetic study exists for the GLOW blend as a combined formulation; SC is the standard route described in community and vendor protocols for the combined blend. Component peptides have been studied SC individually in animal models.

Community-documented protocols describe SC injection of the reconstituted blend into abdominal/lateral thigh subcutaneous fat. The blend itself (BPC-157 + TB-500 + GHK-Cu) has no published PK data as a combined product; route support is inferred from individual component research.

BPC-157: most common route in foundational rodent studies (rats, IP injection at μg/kg and ng/kg doses); TB-500 IP used in some animal protocols

Bioavailability: IP delivers compound directly into the peritoneal cavity for rapid systemic absorption in rodent models. Most BPC-157 preclinical literature uses IP administration.

IP is the dominant route in published BPC-157 rodent research (e.g., hepatoprotective, gastroprotective, and tissue-repair studies). Not a route used for the compounded GLOW blend in human/community settings; cited for component-level preclinical evidence only.

BPC-157: well-studied in rodent work with slightly slower absorption; TB-500: IM used in some musculoskeletal animal protocols and described in research-grade literature

Bioavailability: IM provides slightly slower absorption than IP with more sustained exposure in animal models. Full-length thymosin beta-4 clinical studies also used IM.

IM is documented for BPC-157 and TB-500 component peptides in preclinical literature. Not a primary route for the compounded GLOW blend in community practice.

Full-length thymosin beta-4 (parent of TB-500 fragment): clinical studies used IV and IM routes at varying schedules

Bioavailability: IV administration of full-length thymosin beta-4 has been used in clinical studies; the TB-500 fragment sold in research settings is not typically administered IV.

IV route evidence applies to full-length thymosin beta-4 (Tβ4), not the TB-500 (17-23 fragment or LKKTETQ fragment) component of the GLOW blend. This is component-level clinical evidence, not blend-level.

GHK-Cu: human skin penetration studied in vitro using flow-through diffusion cells on isolated stratum corneum, epidermis, and dermatomed skin; topical GHK-Cu is the most-studied route for this component in human-relevant models

Bioavailability: In vitro human skin study showed copper as tripeptide (GHK-Cu) permeated dermatomed skin with a permeability coefficient of 2.43 ± 0.51 × 10⁻⁴ cm/h; 136.2 ± 17.5 μg/cm² copper permeated over 48 h with 97 ± 6.6 μg/cm² retained as depot. Topical GHK-Cu confirmed to penetrate stratum corneum when properly formulated.

Topical route applies only to the GHK-Cu component of the GLOW blend. BPC-157 and TB-500 are not studied topically in the blend context. A ClinicalTrials.gov record (NCT07437586) lists a topical GHK-Cu gel wound-healing study, but that record's authenticity requires verification (see highStakes).

BPC-157: oral gavage studied in preclinical models with demonstrated systemic bioactivity, particularly in gastrointestinal models; BPC-157 shows resistance to gastric acid degradation

Bioavailability: BPC-157 is considered unusually stable in gastric conditions compared to most peptides, with resistance to enzymatic degradation in acidic environments. Exact oral bioavailability figures remain under investigation. Oral administration of the GLOW blend would provide inconsistent dosing of only the BPC-157 component.

Oral stability data exists only for the BPC-157 component. TB-500 and GHK-Cu lack comparable oral stability/bioavailability data. Oral route is not a standard administration method for the GLOW blend as a combined formulation. Oral stability ≠ oral absorption.

BPC-157: intranasal delivery explored as a method to bypass GI degradation and leverage nasal-to-brain pathway; BPC-157-specific intranasal studies are less numerous than injectable studies

Bioavailability: Intranasal peptide delivery is a recognized research format; direct head-to-head bioavailability comparisons with injection are limited in published literature. Potential for olfactory tract delivery toward CNS targets.

Intranasal route applies only to the BPC-157 component. No published data on intranasal administration of the GLOW blend as a combined formulation. Community-documented intranasal BPC-157 products exist but lack robust PK data.

Animal & human figures are kept visibly separate so studied animal doses are never misread as human guidance.

Sorted A–Z by vendor — never by price

Weekly median $/mg from the live vendor crawl.

Researched storefront prices, bucketed

p25 $1.41 · median $1.64 · p75 $2.00 · 7 researched vendors

Legit, COA-backed band: $1.26–$2.16/mg.

Value rule: don't just buy the cheapest — a price under $3/mg is a red flag. Pair price with COA and independent-test grade.

Estimated cost of research (10 mg)

Vial (best researched price)

$13

Bacteriostatic water (generic estimate)

$6

Syringes / supplies (generic estimate)

$12

What each test proves — general guidance, plus this compound's researched purity data

Purity on the current market (researched)

Vendor-claimed purity for GLOW Blend components is ≥99% per individual peptide (GHK-Cu, BPC-157, TB-500). However, Janoshik Analytical states that peptide purity cannot be measured in blends because impurities of mixed peptides obscure each other; only ID and amount analysis is available for GLOW blends. Independent component testing (Finnrick aggregate, BPC-157) shows pass rates of ~67% across 200 visible tests.

Independent labs cited for this compound

No FDA recalls or market withdrawals specific to 'GLOW Blend' as a named product were found. The blend is not an FDA-approved drug; enforcement has targeted individual peptide vendors and component substances (BPC-157, TB-500) rather than the GLOW Blend formulation itself.

Buyer red-flag checklist

• GLOW Blend is not an FDA-approved drug; no approved NDA/ANDA exists for the formulation or its components (BPC-157, TB-500, GHK-Cu)
• BPC-157 is prohibited under WADA S0 Unapproved Substances category; USADA confirms no legal basis for compounding
• Janoshik states peptide purity cannot be measured in blends — vendor claims of '≥99% purity' for GLOW Blend as a whole are not independently verifiable via standard HPLC
• De-identified community lab test showed 18.18% impurities and significant ratio deviation (TB-500 at 11.31% vs. labeled 14.3%) in one GLOW Blend sample
• Finnrick aggregate BPC-157 data shows 33% test failure rate across 200 visible tests; only 8 of 99 vendors meet strict purity standards
• FDA warning letters (March 2026) targeted RUO peptide vendors selling injectable products with drug claims despite 'research use only' labeling
• TB-500 is often labeled interchangeably with full-length Thymosin Beta-4 (43 amino acids) — composition verification required when sourcing
• Compounded preparations are not standardized across pharmacies; formulations, concentrations, and excipients may differ between products using the same 'GLOW' name

GMP vs research-grade: the chemistry (SPPS + HPLC + MS) is identical — the difference is the quality system.

Underdosing / mislabeling: Finnrick Analytics aggregate data for BPC-157 (a GLOW Blend component) shows 66 of 200 visible tests failed (33% fail rate) across 99 vendors and 674 total tests as of June 2026. This reflects the BPC-157 component market, not GLOW Blend specifically. A de-identified community lab test of a GLOW Blend vial reported GHK-Cu 42.55%, BPC-157 27.97%, TB-500 11.31%, with 18.18% impurities — indicating significant deviation from labeled 50/10/10 ratio in that sample.

• Detention Without Physical Examination of Unapproved New Drugs Promoted In The U.S. Unapproved new drugs marketed with disease-treatment or structure/function claims are subject to DWPE. Peptide products marketed as 'research use only' but promoted with drug claims fall within this alert's scope.66-41
• An RUO label is not an import exemption — CBP judges actual intended use.
• Lyophilized powder is ambient-stable in transit; temperature control needed for > 7-day transit.
• US-warehouse vendors dodge import scrutiny — they cost more but ship more reliably.

Every item dated & sourced

GLOW Blend is not a single named substance on the WADA Prohibited List; however, its component peptides are prohibited. BPC-157 is prohibited under S0 (Unapproved Substances) at all times. TB-500 (Thymosin-β4 and its derivatives) is prohibited under S2.3 (Growth Factors and Growth Factor Modulators). GHK-Cu is not explicitly listed on the WADA Prohibited List (status debated). The blend as a whole is not approved by any global regulatory authority and contains prohibited components for athletes subject to WADA/USADA testing.

No granted patents identified in current seed. Composition-of-matter coverage is limited given the peptide's synthetic origin.

• IACUC / IRB research context
• RUO buyer responsibilities & documentation
• Veterinary / alternative-use where lawful
• Jurisdiction-aware "who may lawfully obtain"

What people discuss

Reported concerns — discussion, not established effects

Reading caveats

• Vendor-affiliated subreddits (e.g., r/NovaPeptides) publishing blend reviews
• Affiliate-marketing aggregator content with discount codes paired with dosing guidance
• RUO disclaimers placed alongside first-person dosing protocols
• SEO-driven review blogs presenting vendor pricing as neutral comparison

Manually researched from reddit, youtube, x— theme weights are research estimates, not live counts; aggregated & de-identified. No individual posts, quotes, or usernames are ever shown.

Relative research / market volume — populated once the activity stream is wired

Inline tooltips for lyophilized, RUO, EU/mg, SPPS, 503A and more.

Toggle plain-language ↔ scientific in the header.

• How to read a COA
• Free base vs acetate
• Understanding evidence grades

RUO blend of BPC-157, TB-500, and GHK-Cu studied preclinically for complementary wound healing, collagen remodeling, and tissue regeneration. Approximately 15 articles are indexed (literature last scanned 2026-05-29). US regulatory status: Research Use Only; blend not independently regulated. Research use only.

Emitted as JSON-LD: ChemicalSubstance · BreadcrumbList · FAQPage.

• Price-drop & back-in-stock alerts
• Regulatory-change email digest
• Print / share this datasheet